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Abstract 
Background: Depression is a prevalent, independent predictor of mortality in patients with heart failure (HF). 
Depression is also common in type 2 diabetes mellitus (T2DM), which is itself an important risk factor for HF. However, 
association of depression with incident HF in T2DM is undefined. The aim of the present study was to evaluate the 
predictive value of depression in predicting incident HF in a community-based cohort of asymptomatic patients with 
T2DM.
Methods: We prospectively recruited 274 asymptomatic T2DM patients ≥ 65 years (age 71 ± 4 year, 56% men) with 
preserved EF and no ischemic heart disease from a community-based population. The Patient Health Questionnaire 
9 (PHQ-9) was used to detect depression, and LV dysfunction was sought with a comprehensive echocardiogram, 
including LV hypertrophy (LVH) and subclinical diastolic function (E/e′). Over a median follow-up of 1.5 years (range 
0.5–3), 20 patients were lost to follow-up and 254 individuals were followed for outcomes.
Results: At baseline, depression was present in 9.5%, LVH was identified in 26% and reduced E/e′ in 11%. Over 
a median follow-up of 1.5 years, 37 of 245 patients developed new-onset HF and 3 died, giving an event rate of 
107/1000 person-years. In a competing-risks regression analysis, depression (adjusted HR 2.54, 95% CI 1.18–5.46; 
p = 0.017) was associated with incident HF and had incremental predictive power to clinical, biochemical and echo-
cardiographic variables.
Conclusion: Depression is prevalent in asymptomatic elderly patients with T2DM, and depression independently 
and incrementally predicts incident HF.
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Background
Heart failure (HF) has been recognized as one of the 
most common and malignant complications of type 2 
diabetes mellitus (T2DM) [1]. HF has been reported 
in > 22% elderly patients with diabetes, and the HF inci-
dence rate was 12.6 per 100 person-years [2]. Among 
elderly patients with DM, the 5-year mortality rate was 
approximately ninefold higher in those who developed 
HF than in those who did not [2]. Depressive symptoms 
are common in the community, but the 19% prevalence 
of depression in patients with T2DM is about double that 
of those without DM [3]. In patients with existing HF, 
comorbid depression and diabetes are associated with a 
higher mortality and rehospitalisation rate [4]. The pres-
ence of depression more than doubled the risk of all-
cause of mortality in HF (hazard ratio [HR] 2.29; 95% CI 
0.94–5.40; p = 0.05), and both DM and depression led to 
a nearly fourfold increment in all-cause mortality (HR 
3.71; 95% CI 1.49–9.25; p = 0.005) [4].
Depression is an independent predictor of HF onset in 
elderly patients with isolated systolic hypertension, which 
is independent of demographic characteristics, medi-
cal history and myocardial infarction risks [5]. Although 
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prior studies have found the association of depression 
and adverse outcomes with diabetes alone or heart fail-
ure alone, the association of depression with incident HF 
in patients with diabetes is unclear, especially as death is 
a competing risk. The current study was undertaken to 
evaluate the extent to which level of depression is able 
to identify risk of incident HF in in a community-based 
cohort of asymptomatic patients with T2DM.
Methods
Study population
We prospectively recruited 274 asymptomatic T2DM 
patients aged ≥ 65 with preserved LVEF from a commu-
nity-based population in Australia. Patients with exist-
ing HF or known ischemic heart disease (reported with 
coronary artery disease including CABG and/or myocar-
dial infarction with regional scar) were excluded, as were 
patients with more than moderate valve disease, history 
of HF, LVEF < 40%, or inability to acquire adequate echo-
cardiographic images for baseline analysis.
Ethics, consent and permissions
All participants provided written, informed consent, 
and the study protocol was approved by the Tasmanian 
Human Research Ethics Committee.
Clinical features
T2DM was based on self-report of this diagnosis includ-
ing the use of relevant medication. Obesity was defined 
as body mass index (BMI)  ≥  30  kg/m2. Demograph-
ics, disease and family history and medication use were 
obtained using a standardized questionnaire. BMI was 
calculated as weight in kilograms divided by height in 
meters squared. In addition to standardized weight and 
height measurements, waist circumference (WC) at 
the midpoint between the lower costal margin and the 
iliac crest was measured to the nearest millimeter by 
a trained examiner. After at least 10 min rest in a quiet 
room, supine resting blood pressure (BP) was meas-
ured twice and averaged in each patient. Active hyper-
tension was defined by a mean systolic blood pressure 
(BP)  ≥  140  mmHg or a diastolic BP  ≥  90  mmHg [6]. 
International Federation of Clinical Chemistry (IFCC) 
standardized hemoglobin A1c (cutoff 64  mmol/mol), 
fasting glucose, creatinine and estimated glomerular 
filtration rate (eGFR) were extracted from pathology 
records. To estimate missing values for HbA1c, we car-
ried out imputation using linear regression equation.
Depression assessment
All participants completed the Patient Health Question-
naire 9 (PHQ-9) at baseline assessment. Each item in 
the PHQ-9 questionnaire corresponds to one of the nine 
DSM-IV criteria for diagnosis of major depression, and 
respondents indicate their level of agreement with each 
item (0 = not at all, 1 = several days, 2 = more than half 
of the days, 3 =  nearly every day). The validated cutoff 
PHQ-9 score ≥ 10 was used as diagnosis for the presence 
of depression [7], and further stratified respondents into 
four categories of depressive symptomatology based on 
the total PHQ-9 score: minimal (0–4), mild (5–9), mod-
erate (10–20), and severe (≥ 20).
Echocardiography
A comprehensive echocardiogram including standard 
transthoracic 2D and Doppler echocardiography was 
performed using the same ultrasound machine (Sie-
mens ACUSON SC2000, 4V1c and 4Z1c probes, Siemens 
Healthcare, Mountain View, CA) in accordance with the 
American Society of Echocardiography guidelines [8, 
9]. Images were saved in raw data format and analyzed 
offline. LV internal dimensions and wall thickness, cham-
ber volumes and valvular morphology were assessed. LV 
mass index (LVMi) was obtained from LV mass measure-
ment using standard criteria and normalized for body 
size (body surface area or height to the power of 1.7). LV 
hypertrophy (LVH) was defined as LVMi (normalized 
for body surface area) > 115 g/m2 for males and > 95 g/
m2 for females. LVEF was measured using the modi-
fied Simpson’s biplane method. LV inflow was obtained 
using pulsed wave Doppler in the apical 4-chamber view; 
peak early (E) and late (A) diastolic velocities, decelera-
tion time and E/A ratio were assessed. Peak early dias-
tolic medial and lateral mitral annular velocity (e′) and 
the ratio of mitral inflow early diastolic velocity to aver-
age e′ velocity were obtained from pulsed tissue Doppler; 
E/e′ > 13 was used as an indicator of diastolic dysfunction 
[10].
Outcomes
The primary endpoint was new-onset of HF, and all-cause 
mortality was considered as a competing risk. Potential 
HF symptoms were assessed through regular follow-up 
phone calls, followed by symptom surveillance question-
naires, clinical visits and repeated echocardiography. 
Records of all-cause hospitalization and mortality were 
obtained from administrative data. The diagnosis of HF 
was established according to Framingham HF criteria; 
symptoms and physical signs that were suspicious for HF 
were reviewed by three independent cardiologists [11].
Statistical analysis
Descriptive data are presented as mean  ±  standard 
deviation (SD) and dichotomous data as subject num-
ber and percentage. Comparisons between the groups 
were performed by independent samples t test; the 
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Kruskal–Wallis test was used for comparison of non-nor-
mally distributed variables. Univariable and multivariable 
stepwise forward linear regression were performed in 
order to identify the variables with significant association 
with PHQ-9 score.
Univariable Cox regression was used to identify the 
predictors of incident HF among clinical, demographic 
and echocardiographic variables. We fitted a competing-
risk model to compute hazard ratio (HR) and 95% confi-
dence interval (95% CI) for the associations between each 
risk factor and incident HF [12]. A multivariable model 
was constructed to determine the independent predic-
tors, guided by univariable analyses and the clinical rel-
evance of the variables. Competing risk methods were 
used to account for the competing risk of death when 
analyzing the endpoint of time to HF. The cumulative 
incidences of HF were calculated and graphically dis-
played separately for patients with and without depres-
sion. Gray’s K-sample test was to compare the cumulative 
incidence estimates of HF between patients with/without 
depression [13], which accounts for all-cause of death 
as a competing risk of HF. All data were analyzed using 
standard statistical computer software (SPSS 22, IBM, 
Chicago, IL and Stata, V.12.0, StataCorp, College Sta-
tion, Texas, USA); p < 0.05 was deemed to be statistically 
significant.
Results
Patient characteristics
Table  1 describes the clinical, echocardiographic and 
biochemical features of 274 asymptomatic T2DM 
patients ≥ 65 years old with preserved EF from the com-
munity who were prospectively recruited and under-
went baseline tests. Table 1 also includes the 254 T2DM 
participants who were included in the final analysis (see 
below). In the total recruited group of 274 subjects, the 
prevalence of LV dysfunction was 13% (by LVH) and 11% 
(by abnormal E/e′ cutoff 13). In the 254 subjects included 
in the final analysis, baseline HbA1c was available in 196 
individuals (age 71  ±  4  years, 55% men). In this sub-
group, the baseline HbA1c was 53.2 ±  11.4  mmol/mol. 
After imputation of missing values, the baseline HbA1c 
was 53.5 ± 10.1 mmol/mol (Table 1).
Depression
Based on PHQ-9 score, 37 (14%) patients had minimal-
to-mild depressive symptoms (PHQ-9 score 5–9), and 
25 (9%) patients were identified as having moderate-to-
severe depressive symptoms (PHQ-9 score 10–20), and 2 
(0.7%) patients were identified as having severe depres-
sive symptoms (PHQ-9 score  ≥  20), and were diag-
nosed as having depression using the cutoff of PHQ-9 
score  ≥  10. Table  2 shows the features associated with 
Table 1 Baseline characteristics (demographic, clinical, 
echocardiographic, physiologic) of 274 elderly asympto-
matic patients with T2DM
Demographic and clinical characteristics
 Age (years) 71 ± 4.4
 Male gender (n, %) 150 (54.7)
 Weight (kg) 85.8 ± 17.2
 Height (cm) 168.4 ± 10.0
 BMI (kg/m2) 30.3 ± 5.9
 Waist circumference (cm) 103.2 ± 13.3
 Obesity (n, %) 135 (49.3)
 Heart rate (n/min) 69 ± 11
 Systolic blood pressure (mmHg) 139 ± 15
 Diastolic blood pressure (mmHg) 81 ± 10
 Hypertension (n, %) 204 (74.4)
 Family history of HF (n, %) 80 (29.2)
 Past chemotherapy (n, %) 25 (9.1)
 Past heart disease (n, %) 16 (5.8)
Medication
 Insulin (n, %) 65 (23.7)
 Metformin (n, %) 184 (67.2)
 ACEi/ARB (n, %) 183 (66.8)
 Beta-blockers (n, %) 15 (5.5)
 Calcium antagonists (n, %) 64 (23.4)
 Diuretics (n, %) 31 (11.3)
 Lipid lowering meds (n, %) 133 (48.5)
Questionnaire
 PHQ-9 score 3.2 ± 4.3
 0–4 210 (76.7)
 5–9 37 (13.5)
 10–20 25 (9.1)
 ≥ 20 2 (0.7)
Echocardiography
 LV ejection fraction (%) 63.1 ± 6.4
 Mitral early-diastolic inflow velocity (E wave) (m/s) 0.65 ± 0.17
 Mitral late-diastolic inflow velocity (A wave) (m/s) 0.83 ± 0.19
 Transmitral diastolic flow velocity ratio (E/A) 0.79 ± 0.22
 Early diastolic mitral annular velocity (e′) (m/s) 0.08 ± 0.02
 Mitral E/e′ septal–lateral ratio (E/e′) 9.2 ± 2.8
 E/e′ ratio > 13 (n, %) 29 (10.6)
 Deceleration time (DT) (s) 246.8 ± 52.4
 LV mass index (g/m2) 85.7 ± 19.0
 LV mass index (g/m1.7) 74.4 ± 20.8
 LV hypertrophy (n, %)a 36 (13.2)
Biochemical characteristics
 HbA1c (mmol/mol) (n = 274) 53.5 ± 10.1
 Fasting glucose (µmol/L) (n = 109) 8.3 ± 3.5
 Creatinine (µmol/L) (n = 186) 81.3 ± 24.0
 eGFR (mL/min/1.73 m2) (n = 187)
 ≥ 90 37 (19.8)
 60–89 115 (61.5)
 45–59 25 (13.4)
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depression; these patients had higher BMI and more cen-
tral obesity, more insulin use and higher HbA1c level. 
However, there was no difference in age, gender, blood 
pressure, heart rate and other risk factors of HF and 
echocardiographic parameters among patients with and 
without depression. The only independent determinant 
of PHQ-9 score detected by linear regression was BMI.
Follow‑up
After a median follow-up time of 1.5  years (range 
0.5–3 years), 2 of 274 T2DM participants (0.7%) were lost 
to follow-up and 18 of 274 participants (6.6%) were alive 
but unable to attend for clinic review (Fig. 1). This group 
was no different from the remaining 254 individuals who 
Table 1 continued
 30–44 9 (4.8)
 15–29 1 (0.5)
a LV hypertrophy was defined as LVMi > 115 g/m2 for males, > 95 g/m2 for 
female
Table 2 Baseline demographic, clinical and echocardiographic variable comparisons among T2DM patients categorized 
by the presence of depression (n = 254)
Italic values indicate significant associations
a LV hypertrophy was defined as LVMi > 115 g/m2 for males, > 95 g/m2 for females
Depression
(n = 25)
No depression
(n = 229)
p
Demographic and clinical characteristics
 Age (years) 70.6 ± 3.8 70.9 ± 4.4 0.418
 Male gender (n, %) 11 (44.0) 131 (57.2) 0.208
 Weight (kg) 92.6 ± 22.8 85.1 ± 16.5 0.122
 BMI (kg/m2) 34.1 ± 7.8 29.8 ± 5.6 0.012
 Waist circumference (cm) 109.0 ± 14.2 102.4 ± 13.1 0.032
 Obesity (n, %) 18 (72.0) 106 (46.3) 0.015
 Heart rate (n/min) 70 ± 11 68 ± 11 0.280
 Systolic blood pressure (mmHg) 138 ± 17 139 ± 14 0.936
 Diastolic blood pressure (mmHg) 80 ± 12 81 ± 9 0.748
 Hypertension (n, %) 19 (76.0) 171 (74.7) 0.985
 Family history of HF (n, %) 10 (40.0) 63 (27.5) 0.191
 Past chemotherapy (n, %) 4 (16.0) 18 (7.9) 0.170
 Past heart disease (n, %) 3 (12.0) 11 (4.8) 0.135
 HbA1c (mmol/mol) 57.6 ± 10.6 53.0 ± 10.0 0.049
 HbA1c > 64 mmol/mol (n, %) 8 (32) 24 (10.5) 0.002
Medication
 Insulin (n, %) 11 (44.0) 49 (21.4) 0.012
 Metformin (n, %) 18 (72.0) 157 (68.6) 0.725
 ACEi/ARB (n, %) 19 (76.0) 152 (66.4) 0.331
 Beta-blockers (n, %) 1 (4.0) 14 (6.1) 0.571
 Calcium antagonists (n, %) 7 (28.0) 54 (23.6) 0.524
 Diuretics (n, %) 4 (16.0) 23 (10.0) 0.360
 Lipid lowering meds (n, %) 14 (56.0) 109 (47.5) 0.426
Echocardiography
 LV ejection fraction (%) 61.5 ± 8.7 63.2 ± 6.2 0.222
 Mitral early-diastolic inflow velocity (E wave) (m/s) 0.62 ± 0.18 0.65 ± 0.16 0.530
 Mitral late-diastolic inflow velocity (A wave) (m/s) 0.81 ± 0.16 0.83 ± 0.19 0.525
 Transmitral diastolic flow velocity ratio (E/A) 0.79 ± 0.21 0.77 ± 0.25 0.693
 Early diastolic mitral annular velocity (e′) (m/s) 0.07 ± 0.01 0.08 ± 0.02 0.852
 Mitral E/e′ septal–lateral ratio (E/e′) 8.6 ± 1.9 9.2 ± 2.8 0.336
 E/e′ ratio > 13 (n, %) 1 (4.0) 25 (10.9) 0.280
 Deceleration time (DT) (s) 231.6 ± 50.4 248.6 ± 52.9 0.129
 LV mass index (g/m2) 87.3 ± 16.1 85.4 ± 19.6 0.602
 LV mass index (g/m1.7) 82.3 ± 27.0 73.6 ± 20.2 0.130
 LV hypertrophy (n, %)a 2 (8.0) 33 (14.4) 0.998
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completed follow-up (Appendix 1: Table  5). The pri-
mary composite endpoint was reached by 40 patients; 37 
patients developed new-onset HF and 3 died, giving an 
event rate of 107/1000 person-years.
Cox regression analysis was performed to analyze 
the association between clinical and biochemical vari-
ables and echocardiographic parameters of interest and 
the time to the primary composite endpoint (Table  3). 
Patients with events were characterized by obesity, worse 
glycemic control, baseline LVEF, LV mass (but not dias-
tolic function parameters), beta blockade and depres-
sion. PHQ-9 scores were significantly associated with 
events, both as a continuous or binomial covariate. When 
PHQ-9 score was categorized into three levels (0–4, 5–9 
and  ≥  10), PHQ-9  ≥  10 was independently associated 
with events. The cumulative survival of the included 254 
elderly asymptomatic T2DM stratified by the severity of 
depression is shown in Appendix 3: Fig. 4. The cumula-
tive survival for patients with PHQ-9 score ≥ 10 was the 
lowest. A multivariable Cox regression model (informed 
by significant univariable clinical associations and echo-
cardiographic parameters of interest) was constructed 
to determine the independent predictors of the com-
posite endpoint (Table  4). Obesity, LVH and depression 
were associated with increased risks of the composite 
endpoint.
Prediction of HF in T2DM
A competing risk analysis that controlled for age, obe-
sity and poor glycemic control was performed to assess 
whether depression and echocardiographic parameters 
of interest were associated with incident HF in elderly 
asymptomatic patients with T2DM (Fig. 2). The baseline 
clinical model, showing an independent effect of obesity 
(p < 0.001), and poor glycemic control (p = 0.02) on inci-
dent events, was improved by addition of echocardio-
graphic features (LVH, p = 0.001). However, the addition 
Fig. 1 Flow chart of study inclusion (n = 254)
Table 3 Univariable Cox regression analysis for primary 
composite endpoint in 254 elderly asymptomatic patients 
with T2DM
Italic values indicate significant associations
a LV hypertrophy was defined as LVMi > 115 g/m2 for males, > 95 g/m2 for 
females
HR (95% CI) p value
Demographic and clinical characteristics
 Age 1.06 (0.99, 1.32) 0.064
 Male gender (yes/no) 1.81 (0.92, 3.56) 0.086
 Weight 1.04 (1.02, 1.05) < 0.001
 BMI 1.10 (1.06, 1.15) < 0.001
 Waist circumference 1.05 (1.03, 1.08) < 0.001
 Obesity (yes/no) 3.61 (1.76, 7.39) < 0.001
 Heart rate 0.99 (0.97, 1.03) 0.727
 Systolic blood pressure 0.99 (0.97, 1.01) 0.314
 Diastolic blood pressure 0.90 (0.99, 1.03) 0.895
 Hypertension (yes/no) 1.07 (0.52, 2.19) 0.854
 Family history of HF (yes/no) 0.70 (0.33, 1.47) 0.349
 Past chemotherapy (yes/no) 1.54 (0.60, 3.93) 0.536
 Past heart disease (yes/no) 1.46 (0.45, 4.74) 0.529
 HbA1c (mmol/mol) 1.03 (1.01, 1.06) 0.009
 HbA1c > 64 mmol/mol (n, %) 3.27 (1.66, 6.43) 0.001
Medication
 Insulin (yes/no) 1.77 (0.92, 3.39) 0.086
 Metformin (yes/no) 0.72 (0.38, 1.36) 0.310
 ACEi/ARB (yes/no) 1.12 (0.57, 2.20) 0.749
 Beta-blockers (yes/no) 3.25 (1.36, 7.77) 0.008
 Calcium antagonists (yes/no) 0.50 (0.21, 1.18) 0.114
 Diuretics (yes/no) 0.91 (0.33, 2.65) 0.909
 Lipid lowering med (yes/no) 1.32 (0.71, 2.48) 0.382
Questionnaire
 PHQ-9 score (continuous) 1.08 (1.01, 1.16) 0.021
 PHQ-9 score ≥ 10 (yes/no) 3.21 (1.41, 7.30) 0.005
 PHQ-9 score (categorical)
 0–4 Ref
 5–9 0.58 (0.18, 1.89) 0.362
 ≥ 10 3.01 (1.32, 6.89) 0.009
Echocardiography
 LV ejection fraction 0.95 (0.90, 0.99) 0.018
 Mitral early-diastolic inflow velocity (E 
wave)
3.46 (0.54, 22.39) 0.192
 Mitral late-diastolic inflow velocity (A wave) 1.81 (0.32, 10.31) 0.503
 Transmitral diastolic flow velocity ratio (E/A) 0.92 (0.16, 5.31) 0.929
 Early diastolic mitral annular velocity (e′) 1.05 (0.86, 1.28) 0.644
 Mitral E/e′ septal–lateral ratio 1.05 (0.94, 1.17) 0.437
 E/e′ ratio > 13 (yes/no) 1.04 (0.37, 2.94) 0.934
 Deceleration time (DT) 0.99 (0.99, 1.00) 0.363
 LV mass index (g/m2) 1.03 (1.02, 1.04) < 0.001
 LV mass index (g/m1.7) 1.03 (1.02, 1.04) < 0.001
 LV hypertrophy (yes/no)a 3.92 (2.04, 7.52) < 0.001
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of depression (p  =  0.017) had incremental predictive 
power to clinical, biochemical and echocardiographic 
variables for the prediction of incident HF (Fig. 2).
The cumulative incidence of HF with time among 
elderly asymptomatic T2DM stratified by depression sta-
tus is shown in Fig. 3. By the end of the follow-up, con-
sidering the competing risk, the cumulative incidence of 
HF was 0.36 in patients with depression and was 0.15 in 
patients without depression. Gray’s test also showed that 
the cumulative incidence of HF was significantly lower 
in patients with depression than those patients without 
depression (p < 0.001).
Discussion
The results of this study show that depression (defined 
as PHQ-9 score ≥  10) was significantly associated with 
increased risk of incident HF during follow-up of asymp-
tomatic elderly patients with T2DM and preserved EF. 
This association was independent of clinical factors 
(including age, gender and BMI) and echocardiographic 
features such as LV hypertrophy and diastolic function. 
The presence of depression increased the likelihood of 
incident HF by 2.5-fold, and increased the composite 
endpoint 3.1-fold, compared with those without depres-
sion. Although depression has been linked with adverse 
outcomes in HF patients, to our knowledge, this is the 
first study to show an independent association between 
depression and incident HF in DM.
Depression and HF
Depression is a common co-morbidity of HF, with vari-
able reports of its prevalence. A meta-analysis of 25 stud-
ies showed depression to be present in 11% HF in NYHA 
(New York Heart Association) functional class I, 20% 
with class II, and approximately 40% of class III and IV 
HF. Depression is more widely diagnosed when this diag-
nosis is made by questionnaire (34%), and less with clini-
cal interview (19%) [14].
Depression is an independent predictor of adverse 
clinical outcomes in HF, and increases the risk of mor-
tality by 40–50% [15] In elderly patients with newly diag-
nosed HF, the presence of depression increased the risk 
of hospital admission by 20%, and depression screening 
has been suggested as a routine assessment at the time 
of HF diagnosis [16]. Even mild depression (defined as 
PHQ-9 score ≥ 5) has been associated with mortality and 
re-hospitalization in HF [17]. Depression is also associ-
ated with a 2.4-fold increment of mortality, independent 
of age, gender, etiology, NYHA class, EF and LV systolic 
dysfunction [18].
Few previous studies have sought whether psycho-
social factors could independently predict incident HF 
Table 4 Cox regression analysis for primary composite endpoint in 254 elderly asymptomatic patients with T2DM
Obesity, BMI ≥ 30 kg/m2; poor HbA1c, ICFFstd-HbA1c > 64 mmol/mol; LVH, left ventricular hypertrophy, cutoff > 115 g/m2 for males, > 95 g/m2 for females; E/e′ ratio, 
cutoff > 13; depression, the score of PHQ-9 questionnaire ≥ 10
HR hazard ratio, CI confidence interval
Italic values indicate significant associations
a In the multivariate cox model, obesity, poor HbA1c, LVH and depression were entered into the model
b In the multivariate cox model, obesity, poor HbA1c, E/e′ and depression were entered into the model
c In the multivariate cox model, age, male gender, obesity, poor HbA1c, LVH, E/e′ and depression were entered into the model
Variable No. of patients No. of HF No. of death Unadjusted HR (95% 
CI)
p value
LVH‑adjusted
HR (95% CI)a
p value
E/e′‑adjusted
HR (95% CI)b
p value
Adjusted HR
(95% CI)c
p value
Age 254 37 3 1.06 (0.99, 1.13)
0.064
– – 1.06 (0.99, 1.14)
0.055
Male gender 142 25 3 1.81 (0.92, 3.56)
0.086
– – 1.36 (0.61, 2.92)
0.466
Obesity 124 29 1 3.61 (1.76, 7.39)
< 0.001
2.87 (1.38, 5.98)
0.005
3.27 (1.58, 5.75)
0.001
2.97 (1.44, 6.30)
0.004
HbA1c 32 10 2 3.27 (1.66, 6.43)
0.001
2.04 (0.99, 4.22)
0.054
2.47 (1.22, 5.00)
0.012
2.01 (0.93, 4.10)
0.077
LVH 35 13 1 3.92 (2.04, 7.52)
< 0.001
3.24 (1.65, 6.38)
0.001
– 2.67 (1.25, 5.99)
0.011
E/e′ 26 4 0 1.04 (0.37, 2.94)
0.934
– 1.11 (0.39, 3.18)
0.845
0.82 (0.26, 2.52)
0.724
Depression 25 7 0 3.21 (1.41, 7.30)
0.005
2.80 (1.16, 6.76)
0.022
2.39 (1.01, 5.67)
0.048
3.14 (1.27, 7.74)
0.013
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[5, 19, 20]. Abramson et  al. [5] first found that depres-
sion, as defined by Center for Epidemiological Stud-
ies Depression Scale (CES-D)  ≥  16, was independently 
associated with a substantial increase in the risk of HF 
among elderly patients with isolated systolic hyperten-
sion. Williams et al. [20] found an independent associa-
tion between depression (CES-D ≥ 20, and incident HF 
among elderly women but not elderly men. The results 
from prospective cohort studies are contradictory—the 
Nord-Trøndelag Health (HUNT) Study demonstrated 
the prospective association of self-reported depression 
at baseline with future HF in a dose–response manner, 
independent of a large number of baseline cardiovascu-
lar risk factors, acute myocardial infarction (AMI) and 
several chronic disorders [19]. However, the Multi-Ethnic 
Study of Atherosclerosis (MESA) found no significant 
Model 1 Model 2 Model 3 
Chi-square 
P for chi-square 
change
25.63 40.92 P<0.001 
51.44 
P<0.001 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
Age 1.05(0.98,1.12) 0.131 
1.02(0.99,1.11) 
0.124 
1.07(1.01,1.14) 
0.034 
Male gender 1.54(0.78,3.06) 0.212 
1.10(0.52,2.32) 
0.798 
1.14(0.53,2.44) 
0.738 
Obesity 4.49(2.12,9.52) <0.001 
3.85(1.83,8.12) 
<0.001 
3.55(1.64,7.66) 
0.001 
Poor HbA1c 2.06(1.11,3.83) 0.022 
2.41(1.27,4.58) 
0.007 
2.29(1.18,4.45) 
0.014 
LVH 3.51(1.67,7.37) 0.001 
3.48(1.60,7.58) 
0.002 
Abnormal E/e’ 0.90(0.31,2.63) 0.850 
0.99(0.32,3.02) 
0.980 
Depression 2.54(1.18,5.46) 0.017 
Abbreviations: HR=hazard ratio; CI=confidence interval;  
Obesity, BMI 30kg/m2; Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; LVH, left ventricular hypertrophy, 
cutoff >115 g/m2 for males, >95 g/m2 for females; Abnormal E/e’ ratio, cutoff >13; Depression, the score of 
PHQ- . 
Fig. 2 Prediction of incident HF in elderly asymptomatic patients with T2DM (competing risk analysis). LVH and depression showed incremental 
value over clinical parameters for incident HF
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association between depression (CES-D scale ≥ 16), and 
subsequent HF in an older population. However, in par-
ticipants reporting fair/poor health status at baseline, this 
association was significant [21]. It is certainly plausible 
that sympathetic overactivity might be associated with 
both HF mortality and HF incidence, but this remains 
unproven.
Depression and diabetes
About 20–30% of elderly patients with diabetes suffer 
from clinical depression, and around 10% of them have 
major depression [22]. Even though the relationship 
between depression and diabetes is incompletely under-
stood, it is clear that depression has an adverse impact 
on the course of diabetes, and diabetes complications 
may result in both the risk of depression and worsening 
the course of depression. Their association is primar-
ily driven by somatic-affective symptoms of depression 
[23]. Additionally, the duration of depression lasts longer 
(usually  ≥  2  years) in most diabetic patients and the 
relapse rate is relatively high [24]. A previous study with 
10-year follow-up also showed that all-cause of mortal-
ity increased with the severity of depression in diabetic 
subjects [25].
HF in diabetes
Numerous epidemiological studies have indicated the 
strong association between diabetes and the develop-
ment of HF [2, 26]. The underlying mechanisms are 
multiple, but there is a growing recognition of a primary 
myocardial disease process—“diabetic cardiomyopa-
thy”—that may lead to LV dysfunction, and subsequently 
HF. Hyperinsulinemia, inflammation and oxidative stress 
result in increased fatty acid metabolism and fetal gene 
expression [27]. The resulting pathophysiological changes 
include impaired myocardial relaxation and cardiomyo-
cyte resting tension, activation of the renin–angiotensin 
system (leading to vasoconstriction, salt and water reten-
tion, and fibrosis) and diabetic autonomic neuropathy. 
These changes lead to impaired diastolic and systolic 
function [28]. Furthermore, overweight has been proved 
to have a greater effect on LV function in diabetes than in 
non-diabetes [29]. In our study, obesity has emerged as 
an important association of incident HF.
Several shared pathophysiological mechanisms may 
link T2DM, depressive symptoms and incident HF. Pro-
inflammatory cytokines and platelet activation, rhythm 
disturbances, neurohormonal activation, endothe-
lial dysfunction and hypercoagulability are present in 
patients with depression [30]. These pathophysiological 
changes adversely influence the cardiovascular system 
and have been postulated to play an important role in 
the development and progression of HF [30]. Endothe-
lial dysfunction plays an important role in cardiovascu-
lar homeostasis by producing various vascular regulators 
that mediate fibrinolysis, hypercoagulability, platelet 
activation and vascular tone, disturbances of which con-
stitute the step linking diabetes to cardiovascular events 
[31]. Hyperglycemia and insulin resistance are associ-
ated with endothelial dysfunction [32] and cardiac dam-
age [31]. Impaired nitric oxide production and oxidative 
stress may also lead to endothelial dysfunction, impaired 
vasodilation and large vessel impairment [31]. Hypergly-
cemia and hyperinsulinemia have also been significant 
contributors to cardiovascular complications through 
their role in stimulating coagulation and impairing 
fibrinolysis [33]. Pro-inflammatory cytokines are com-
mon in diabetes and significantly increase the risk of 
progression of cardiovascular complications at all stages 
[34]. Additionally, patients with depression are more 
likely to take up risky lifestyles and behaviors and more 
likely to show non-adherence to medical regimens and 
behavior recommendations that affects the prognosis of 
HF [35]. Depression may be also involved with the lower 
social support that is implicated in the development of 
HF.
Limitation
In the present study, the population were selected from 
the community with preserved EF, so diabetes patients 
with established asymptomatic LV systolic dysfunction 
were excluded. We did not have data on brain natriuretic 
peptide (BNP). Although this biomarker has an estab-
lished role in the acute care setting to assist the diagnosis 
of congestive heart failure and in predicting long-term 
outcomes, its utility for the early detection of HF with 
preserved ejection fraction (HFpEF) is more contro-
versial. Its response to raised filling pressure is blunted 
Fig. 3 Cumulative incidence estimates of HF in elderly asymptomatic 
T2DM stratified by patients with and without depression
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in overweight patients compared with normal weight 
patients, regardless of the presence or absence of cardio-
vascular disease [36].
We used self-reported measures of symptoms of 
depression rather than diagnostic interviews. However, 
the use of the PHQ-9 survey for screening depression 
has been validated and has been recommended by the 
American Heart Association for the diagnosis of depres-
sion in coronary heart disease [37]. We acknowledge that 
the lower sensitivity of PHQ-9 relative to other markers 
[38] means that it may not capture all patients. However, 
its high specificity can identify patients at high risk for 
adverse cardiovascular events. While the study shows a 
connection of depression with LV dysfunction, it does 
not explain the reasons for depression. In our study, the 
factor associated with depression was advanced BMI. 
Previous research has demonstrated the association of 
diabetes-related complications, longer duration of dia-
betes, more demanding regimens, inactivity, current 
smoking and overweight as potential risk factors for 
depression in T2DM [39].
While we excluded patients with reported history of 
CAD including CABG and/or AMI with regional scar, 
testing for occult CAD was not possible in this commu-
nity-based study. It is therefore possible that some of the 
abnormal cardiac function signal is attributable to coro-
nary artery disease. In addition, the blood examination 
in the cohort such as BNP or NT-pro BNP were not part 
of this study. Lastly, despite the longitudinal study design 
and high-risk nature of this population, the number of 
events was relatively small.
Conclusion
In this community cohort of asymptomatic patients with 
T2DM, depression was prevalent, and significantly asso-
ciated with incident HF over 2-years of observation. This 
association is not explained by baseline demographic 
characteristics, glycemic control and LV dysfunction 
[including LV hypotrophy and subclinical diastolic dys-
function (evidenced by E/e′)]. The mechanism of this 
association requires further investigation, and although it 
remains unclear as to whether a depression intervention 
in T2DM may prevent HF, depressed patients may war-
rant closer monitoring for the development of HF.
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